Guideline Recommendations for Sedating Antidepressants in Chronic Insomnia

Guideline Positioning

The American Academy of Sleep Medicine (2008) classifies trazodone and mirtazapine as third‑line sedating antidepressants for chronic insomnia, to be used only after benzodiazepine‑type hypnotics or ramelteon have failed or when comorbid depression/anxiety is present. 1
The VA/DoD guideline (2020) strongly recommends against trazodone for primary chronic insomnia because it does not produce objective sleep improvements and has an unfavorable adverse‑effect profile. 4
Neither trazodone nor mirtazapine is FDA‑approved for insomnia; both are off‑label uses with relatively weak efficacy evidence compared with approved hypnotic agents. [2][4]

Trazodone is associated with a higher risk of treatment discontinuation (Risk Ratio = 2.30) and a greater overall adverse‑effect rate (RR = 1.18) versus placebo; sleep‑related adverse effects are especially elevated (RR = 4.31). 4
Common adverse events with trazodone include daytime drowsiness (≈ ≥ 20 %), decreased appetite, and headache (≈ 30 %); older adults have an increased risk of falls and hyponatremia. 4
Both agents require informed consent for off‑label use, screening for contraindications (e.g., cardiac disease or priapism risk with trazodone; seizure history with mirtazapine), and careful review of drug interactions, particularly with other serotonergic medications. 4

For sustained sedation without tolerance, initiate trazodone 25–50 mg taken about one hour before bedtime with food; if needed, titrate to 50–75 mg, avoiding doses > 100 mg because higher doses may reduce efficacy. 4
When treating depression with insomnia and weight‑gain is a concern, trazodone 150–300 mg (divided doses) provides antidepressant benefit with less weight gain than mirtazapine; sexual dysfunction risk is lower with both agents compared with SSRIs. 5

First‑line therapy for primary chronic insomnia should be cognitive‑behavioral therapy for insomnia (CBT‑I); if pharmacotherapy is required, benzodiazepine‑type receptor agonists are preferred before considering sedating antidepressants. [1][4]
Objective sleep‑outcome data for trazodone show minimal improvements (≈ 10 min shorter sleep latency, ≈ 22 min longer total sleep time, ≈ 8 min less wake after sleep onset), all below clinically significant thresholds, supporting its limited evidence base. 4